TY - JOUR
T1 - Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
AU - Lipton, Jeffrey H.
AU - Brümmendorf, Tim H.
AU - Gambacorti-Passerini, Carlo
AU - Garcia-Gutiérrez, Valentin
AU - Deininger, Michael W.
AU - Cortes, Jorge E.
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/11
Y1 - 2022/11
N2 - The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myeloid leukemia (CML). Although there are some common class-wide side effects, differences in safety profiles between TKIs allow physicians and patients to personalize treatment plans. Treatment selection depends on several factors, such as age, disease risk, comorbidities, and concomitant medications. In second- and later-line settings, response to previous TKIs and mutation analyses should also be used to guide TKI selection. Several strategies can be used to manage adverse events (AEs) that emerge during treatment, e.g., dose reductions/interruptions, monitoring, treatment of AEs, lifestyle modifications, prophylactic therapy, and other supportive care strategies. This review summarizes the safety profiles of the currently approved TKIs and how they impact treatment selection in the first- and later-line settings of CML, particularly regarding patient comorbidities and concomitant medications. Additionally, strategies to manage AEs of special interest with TKIs are reviewed.
AB - The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myeloid leukemia (CML). Although there are some common class-wide side effects, differences in safety profiles between TKIs allow physicians and patients to personalize treatment plans. Treatment selection depends on several factors, such as age, disease risk, comorbidities, and concomitant medications. In second- and later-line settings, response to previous TKIs and mutation analyses should also be used to guide TKI selection. Several strategies can be used to manage adverse events (AEs) that emerge during treatment, e.g., dose reductions/interruptions, monitoring, treatment of AEs, lifestyle modifications, prophylactic therapy, and other supportive care strategies. This review summarizes the safety profiles of the currently approved TKIs and how they impact treatment selection in the first- and later-line settings of CML, particularly regarding patient comorbidities and concomitant medications. Additionally, strategies to manage AEs of special interest with TKIs are reviewed.
KW - Adverse events
KW - Chronic myeloid leukemia
KW - Long-term
KW - Safety
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85130350866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130350866&partnerID=8YFLogxK
U2 - 10.1016/j.blre.2022.100968
DO - 10.1016/j.blre.2022.100968
M3 - Review article
C2 - 35570071
AN - SCOPUS:85130350866
SN - 0268-960X
VL - 56
JO - Blood Reviews
JF - Blood Reviews
M1 - 100968
ER -